Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: A phase II multicenter trial

Vito Lorusso, Luigi Manzione, Ferdinando De Vita, Mauro Antimi, Francesco Paolo Selvaggi, Mario De Lena

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We determined the activity and toxicity of gemcitabine plus cisplatin in patients with inoperable or metastatic transitional cell carcinoma of the urinary tract. Materials and Methods: A total of 54 patients with transitional cell carcinoma, measurable disease and Eastern Cooperative Oncology Group performance status 2 or greater were enrolled in this multicenter phase II trial. Previous adjuvant or neoadjuvant therapy for locally advanced disease was acceptable if it had been completed more than 1 year before study entry. Every 4 weeks patients received 1,000 mg./m.2 gemcitabine intravenously on days 1, 8 and 15, and 70 mg./m. cisplatin intravenously on day 2. Results: All patients were evaluable for response and toxicity. Notably only 7 of the 54 patients (13%) previously received chemotherapy in an adjuvant or neoadjuvant setting. Overall we observed 26 objective responses (48%), of which 15% were complete. Median time to progression was 23 weeks and median survival was 54 weeks. Treatment was well tolerated. The main toxicities were leukopenia (grade 3 in 28% and grade 4 in 11% of patients), anemia (grade 3 in 34% and grade 4 in 6%) and thrombocytopenia (grade 3 in 14% and grade 4 in 6%). Other relevant side effects were nausea and vomiting in 20% of cases, fever in 24%, alopecia in 22%, renal failure in 7.4% and mucositis in 2%. Conclusions: Combined cisplatin plus gemcitabine is highly active in advanced transitional cell carcinoma of the urinary tract with manageable toxicity. The response rate, time to treatment failure and overall survival appeared to be comparable to those achieved with combined methotrexate, vinblastine, doxorubicin and cisplatin. Conversely toxicity appeared lower. Evaluation of this regimen in randomized studies with methotrexate, vinblastine, doxorubicin and cisplatin is strongly suggested.

Original languageEnglish
Pages (from-to)53-56
Number of pages4
JournalJournal of Urology
Volume164
Issue number1
Publication statusPublished - Jul 2000

Keywords

  • Carcinoma, transitional cell
  • Cisplatin
  • Neoplasm metastasis
  • Urinary tract

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: A phase II multicenter trial'. Together they form a unique fingerprint.

Cite this